Save
Email
Print
ShareDec. 8, 2009 — Researchers from Yale University and Mirna Therapeutics, Inc., reversed the growth of lung tumors in mice using a naturally occurring tumor suppressor microRNA. The study reveals that a tiny bit of RNA may one day play a big role in cancer treatment, and provides hope for future patients battling one of the most prevalent and difficult to treat cancers.
"This is the first time anybody has shown a positive effect of microRNAs in shrinking lung cancer," said Frank Slack, Ph.D., co-senior author of the paper, researcher at the Yale Cancer Center and professor of molecular, cellular & developmental biology.
The tumors in mice with non-small cell lung cancer shrank after the Yale team delivered an intranasal dose containing a type of micro-RNA called let-7, the authors reported in the Dec. 7 issue of the journal Oncogene. MicroRNAs are small bits of genetic material most often associated with transmission of information encoded in DNA. However in the past decade microRNAs have been shown to play crucial roles in gene regulation and/or gene silencing
The Yale team also found that mice without let-7 developed cancer, supporting their hypothesis that the microRNA acts as a tumor suppressor. The tumors in mice that received let-7 were not eliminated, but reduced by 66 percent, the study showed. The team is currently studying whether let-7 therapy in combination with chemotherapy and radiation can induce full remission.
Slack noted let-7 is absent in many cancers and acts upon a gene known to play a role in about a quarter of all human cancers.
"We hope it will be valuable in the treatment of many other forms of cancer," he said.
The research was conducted as part of collaboration between Yale and Mirna Therapeutics Inc, a biotechnology company in Austin, Texas. Joanne B. Weidhaas, MD/Ph.D. of Yale and Andreas G. Bader, Ph.D. of Mirna were co-senior authors of the paper. Other Yale authors on the paper are first author Phong Trang, Pedro P. Medina and Robert Homer; other Mirna authors are Jason F. Wiggins, Lynnsie Ruffino, Kevin Kelnar, Michael Omotola and David Brown, Ph.D.
Funding for the work came from the National Institutes of Health, Connecticut Department of Health, The Hope Funds for Cancer Research and Mirna Therapeutics, Inc.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Yale University.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
more 
